They therefore require prompt recognition and management. We report the case of a woman presenting with widespread joint pain and stiffness 6 hours after her first pembrolizumab infusion. She had no ...

If pembrolizumab is permanently discontinued for any other reasons, the subject may still be allowed to proceed to Part B and receive the T cell infusion only, but once systemic corticosteroids or ...

One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.

It’s important to tell your doctor or nurse right away if you have any of these symptoms while getting a pembrolizumab infusion. Autoimmune reactions: This drug basically removes one of the safeguards ...

Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug ...

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

Immune-related AEs and infusion reactions occurred in 42% of pembrolizumab-treated patients; these were grade 3 to 5 in 10% of patients, led to treatment discontinuation in 6%, and led to death in 1 ...

In stage 4, a tumor that began in the liver has spread to either nearby lymph nodes and/or distant lymph nodes and organs.Liver cancer is relatively rare, with under 42,000 cases being diagnosed each ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, ...